泽诺库珠单抗(Zenocutuzumab-zbco) - 药物靶点：HER2 x HER3_在研适应症：NRG1 融合的胰腺腺癌，NRG1融合阳性非小细胞肺癌，ER阳性HER2低表达乳腺癌_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

HER3 x HER2 Biclonics、Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer、Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)

+ [8]

靶点

HER2 x HER3

作用方式

拮抗剂

作用机制

HER2拮抗剂(受体蛋白酪氨酸激酶 erbB-2拮抗剂)、HER3拮抗剂(受体酪氨酸蛋白激酶erbB-3拮抗剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症

NRG1 融合的胰腺腺癌NRG1融合阳性非小细胞肺癌ER阳性HER2低表达乳腺癌+ [1]

非在研适应症

转移性去势抵抗性前列腺癌

原研机构

Merus NV

在研机构

Merus NV

非在研机构-

权益机构

Partner Therapeutics, Inc.

Merus NV

最高研发阶段批准上市

首次获批日期

美国 (2024-12-04),

NRG1 融合的胰腺腺癌NRG1融合阳性非小细胞肺癌

最高研发阶段(中国)无进展

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 43197L

来源: *****

Sequence Code 26101535H

来源: *****

Sequence Code 315583329H

来源: *****

关联

4

项与泽诺库珠单抗相关的临床试验

NCT05588609

/ Terminated临床2期

A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses:
Group A: NRG1+ NSCLC Group B: mCRPC

开始日期2022-11-17

申办/合作机构

Merus NV

NCT03321981

/ Completed临床2期

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2.
MCLA-128 (zenocutuzumab) is given in combinations in two metastatic breast cancer (MBC) populations, Human Epidermal Growth Factor Receptor (HER) 2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low HER2 expression (Cohort2).
Two combinations treatments will be evaluated in Cohort 1, the doublet and triplet. Initially zenocutuzumab is given in combination with trastuzumab in the doublet. After the safety of the doublet has been assessed in 4-6 patients, MCLA-128 is given in combination with trastuzumab and vinorelbine in the triplet, in parallel to the efficacy expansion of the doublet.
The doublet and triplet combinations are both evaluated in two steps with an initial safety run-in followed by a cohort efficacy expansion. In total up to 40 patients evaluable for efficacy are included in both the doublet and triplet.
In Cohort 2 zenocutuzumab is administered in combination with the same previous endocrine therapy on which progressive disease is radiologically documented. A total of up to 40 patients evaluable for efficacy are included in the Cohort 2.

开始日期2018-01-15

申办/合作机构

Merus NV

NCT02912949

/ Active, not recruiting临床2期

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)

开始日期2015-01-01

申办/合作机构

Partner Therapeutics, Inc.

100 项与泽诺库珠单抗相关的临床结果

登录后查看更多信息

100 项与泽诺库珠单抗相关的转化医学

登录后查看更多信息

100 项与泽诺库珠单抗相关的专利（医药）

登录后查看更多信息

34

项与泽诺库珠单抗相关的文献（医药）

2025-12-31·mAbs

Antibodies to watch in 2025

Review

作者: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

2025-08-06·ONCOLOGY-NEW YORK

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

作者: Zainab Ibrahim Mbbs ; Hamza Nazir Mbbs ; Wardak, Abdul Baseer ; Sanan Rasheed Mbbs ; Adnan Bhat Md ; Ayesha Aman Mbbs ; Umer Farooq Mbbs ; Waheed, Aiman ; Musharaf Khalid Bhutta Mbbs ; Gul, Muhammad Hamza

Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non–small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. In early-phase clinical trials, it has shown an objective response rate of approximately 34% in HER2-amplified NSCLC and a disease control rate exceeding 70% in pancreatic adenocarcinoma with NRG1 fusions. By disrupting HER3-driven oncogenic signaling, zenocutuzumab effectively inhibits tumor proliferation and enhances therapeutic outcomes. Its safety profile remains favorable, with most adverse effects being mild to moderate. This editorial explores the clinical potential of zenocutuzumab in reshaping treatment strategies for NSCLC and pancreatic adenocarcinoma.

2025-06-01·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Bispecific Antibodies in Non–Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration

Review

作者: Johnson, Melissa ; Naqash, Abdul Rafeh ; Mitchell, Carley ; Pannu, Sagal ; Carlisle, Jennifer W. ; Aijaz, Ayesha ; Wolner, Zachary ; Hsu, Melinda

Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory disease subsets. Recent US Food and Drug Administration approvals—including amivantamab, an epidermal growth factor receptor (EGFR)/mesenchymal-epithelial transition factor–targeting monoclonal antibody for EGFR exon 20 insertions and frontline EGFR-mutant (Exon 19 and 21) NSCLC, and zenocutuzumab for tumors harboring neuregulin 1 fusions—highlight their expanding therapeutic footprint. However, a new spectrum of on-target toxicities and implementation challenges are essential considerations as part of this innovation. This review dissects the evolving clinical data for bispecific antibodies in NSCLC, focusing on amivantamab, and provides a practical framework for managing dermatologic, infusion-related, and class-specific adverse events. We explore quality-of-life outcomes, financial toxicity, and the role of subcutaneous formulations in improving patient adherence and treatment experience. Furthermore, we highlight an emerging PD-1/vascular endothelial growth factor-A bispecific antibody (ivonescimab) and its potential to reshape frontline therapy paradigms in NSCLC. By integrating clinical trial evidence with real-world considerations, this review aims to equip oncologists with the tools to optimize the use of bispecific antibodies in NSCLC and guide future therapeutic integration.

131

项与泽诺库珠单抗相关的新闻（医药）

2025-09-30

·美迪西Medicilon

恒瑞医药子公司4个注射液药物获批临床 | 1分钟药闻速览

医线药闻 9月29日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于SHR-7787注射液、SHR-4849注射液、贝伐珠单抗注射液、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-7787注射液为1类治疗用生物制品，适应症为恶性实体瘤；SHR-4849注射液是公司自主研发的一款以DLL3为靶点的抗体药物偶联物，拟用于治疗晚期恶性实体瘤；贝伐珠单抗是一种人源化抗VEGF单克隆抗体；阿得贝利单抗注射液是人源化抗PD-L1单克隆抗体，用于成人非小细胞肺癌。 9月30日，强生宣布，美国FDA已批准其抗IL-23抗体Tremfya（guselkumab）用于治疗年龄在6岁及以上、体重不低于40公斤的中重度斑块型银屑病（PsO）或活动性银屑病关节炎（PsA）儿童患者，其中PsO患者需具备资格接受系统性疗法或光疗。根据新闻稿，此次批准使Tremfya成为获批用于治疗上述儿童患者群体的首个IL-23抑制剂。 9月29日，卫材和渤健宣布，其人源化抗可溶性聚集淀粉样蛋白-β（Aβ）单克隆抗体仑卡奈单抗（商品名：乐意保®），每四周进行一次静脉（IV）维持剂量给药方案已获中国国家药品监督管理局（NMPA）批准。 9月28日，CDE 官网显示，上海昂昇生物医药科技有限公司申报的「Astem-101人脐带间充质干细胞(hUC-MSCs)注射液」，正式获得临床试验默示许可。这是中国首款获得卫健委和药监局双备案的干细胞药物，Astem-101将针对“穷尽现有治疗仍无效的2型糖尿病合并中、重度勃起功能障碍”进行治疗。投融药事 9月29日，Genmab宣布与Merus达成收购协议，将以每股97美元的价格收购后者的全部股份，总金额约为80亿美元。预计该交易将于2026年第一季度初完成。Merus目前在纳斯达克的市值为52亿美元。公开信息显示，Merus是一家专注于开发双抗药物的荷兰生物技术公司，其主要在研产品包括HER3/HER2双抗Zenocutuzumab（MCLA-128）、LGR5/EGFR双抗Petosemtamab（MCLA-158）、EGFR/c-Met双抗MCLA-129、PD-1/CD3双抗ONO-4685和PD-1/TGFBR2双抗INCA33890，其中Zenocutuzumab（商品名：Bizengri）已于2024年12月在美国获批上市，适应症为既往全身治疗期间或之后疾病进展的携带NRG1基因融合的晚期、不可切除或转移性非小细胞肺癌（NSCLC）成人患者和胰腺癌成人患者。科技药研 9月25 日，美国国家衰老研究所的研究人员在 Nature 子刊Nature Aging 上发表了题为：A distinct population of CD8⁺ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression 的研究论文。研究团队提出了一种新机制——在衰老过程中，癌症的发展也得到了功能健全的 CD8⁺ T 细胞的帮助。 [1]Bodogai, M., Park, B., Braikia, FZ. et al. A distinct population of CD8+ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression. Nat Aging (2025). https://doi.org/10.1038/s43587-025-00966-3

并购申请上市临床申请

2025-09-30

·PRNewswire

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction

Genmab has entered into a definitive agreement to acquire Merus in an all-cash transaction for a total consideration of USD 8.0 billion, making it one of the largest acquisitions of a European biotech company to date Merus is a clinical-stage oncology company developing bi/tri-specific antibodies, with a pipeline including petosemtamab for head and neck squamous cell carcinoma and other malignancies EQT Life Sciences has been an investor in Merus since 2010, supporting the Company at board level in its growth from a start-up company to a NASDAQ-listed clinical-stage biotech with multiple late-stage oncology assets STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- EQT Life Sciences, a leading European life sciences venture capital firm, is pleased to share that Genmab (CPH: GMAB) has entered into a definitive agreement to acquire its portfolio company Merus (NASDAQ: MRUS) for a total consideration of USD 8.0 billion. This transaction represents one of the largest M&A deals in European biotech and underscores the value of Merus' innovative clinical pipeline addressing significant unmet needs in oncology. Merus, based in Utrecht, the Netherlands, is a clinical-stage biotech company developing innovative bispecific and trispecific antibody therapeutics for the treatment of cancer. The company's products include petosemtamab, in development for head and neck squamous cell carcinoma and other malignancies, and zenocutuzumab, an approved product for patients with NRG1 fusion–driven tumors such as pancreatic and lung cancers. Despite significant advances in oncology, patients with these tumor types continue to face poor prognoses and limited treatment options, underscoring the urgent need for more effective therapies. Over the past year, Merus' lead program petosemtamab, has delivered best-in-class Phase 2 results in both first-line and later-line head and neck cancer, significantly outperforming historical benchmarks and positioning itself as a potential standard-of-care redefining therapy. In addition, Phase 2 trials are ongoing in colorectal cancer in first-, second- and third-line settings. With two FDA Breakthrough Therapy Designations, petosemtamab is well positioned to transform outcomes in head and neck cancer and potentially other oncology indications. EQT Life Sciences (formerly LSP) first invested in Merus in 2010 from its LSP 4 fund, co-leading the company's first institutional financing. At that time, Merus was still an early-stage preclinical company with a very small team. From 2010 to 2020, EQT was represented on the company's board by Partner John de Koning, providing active strategic support as Merus advanced its pipeline into the clinic and successfully developed multiple antibody programs, including its lead asset. John de Koning, Partner at EQT and former board member at Merus, said: "It has been a great honor to support Merus from its early beginnings to a NASDAQ-listed clinical-stage biotech with more than 300 employees. The acquisition agreement with Genmab highlights the strength of Merus' innovative platform and pipeline and is a testament to the team's vision and leadership. This landmark transaction not only reflects the company's potential to transform cancer care but also represents one of the largest biotech acquisitions ever in Europe. Importantly, it is also a step toward making better treatments available to patients and improving both quality of care and quality of life, underscoring the importance of venture capital in bringing scientific ideas to patients." Contact: EQT Press Office, [email protected] This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期并购临床结果

2025-09-29

·Biotech前瞻

从普方到Merus丨Genmab百亿美元并购，看中ADC与双抗两条赛道

点击蓝字关注我们本期看点 ADC和双抗，都是时下火热的赛道，国内一众Biotech企业及老牌药企纷纷布局，并依托潜力重磅在研产品获得MNC的关注和BD，进一步追推两条赛道获得更多注意和研发加速。本文也聚焦既往鲜少报道的Genmab公司及其近年来的并购策略。本期内容 01 并购加速：Genmab的双赛道布局 02 收购普方生物，意在FRα ADC 03 Merus：双抗差异化布局并上市 04 总结与展望【01 并购加速：Genmab的双赛道布局】对于Genmab的关注，源自于2024年4月，Genmab以18亿美元全现金收购普方生物，补强抗体偶联药物（ADC）管线。而近日，Genmab宣布以80亿美元收购荷兰双抗公司Merus，押注双特异性抗体（BsAb）。由此也可见出Genmab的战略抉择还是行业少见，同时布局技术路线截然不同的ADC和双抗赛道的企业不多，布局双抗ADC的倒是不少。本文也分别介绍下具体的产品选择和潜力未来。 02 收购普方生物，意在FRα ADC Genmab收购的普方生物是一家临床阶段的生物技术公司，致力于为治疗包括卵巢癌和其他FRα表达实体瘤在内的特定癌症研发下一代抗体偶联药物（ADC）和ADC技术，研发管线包含多种针对实体瘤和血液恶性肿瘤的在研ADC药物。普方生物中最核心的ADC药物为Rina-S, 以叶酸受体α(FRα)为靶点的ADC药物和新型EGFR/cMET双特异性抗体ADCPRO1286。 Rinatabart Sesutecan（Rina-S）研发进展：目前已进入卵巢癌和子宫内膜癌的II期临床，2024年10月1日，Genmab更是在Clinicaltrials.gov注册了其 III期临床试验，计划入组530例铂类耐药晚期卵巢癌患者，与化疗进行头对头对照，预计2027年完成初步结果。战略意义： FRα(叶酸受体α)是一种位于细胞膜上的叶酸结合蛋白，参与调控肿瘤细胞的浸润、增殖和转移。该受体在多种肿瘤组织中广泛高表达，如卵巢癌（76%-89%）、三阴乳腺癌（35%-68%）、非小细胞肺癌（14%-74%），而在正常组织中几乎不表达，因此FRα是开发抗肿瘤药物的理想靶点。 FRα是卵巢癌重要靶点之一，竞争格局中虽有ImmunoGen的Elahere率先获批，但Genmab选择通过全资收购并快速推进III期，显示出其在妇瘤赛道抢占高地的决心。 FRα靶向药物在癌症诊断和治疗中的临床应用（cited by：Scaranti, M.S. et al.Nat Rev Clin Oncol 17,349-359(2020).) 此外，普方还拥有新型EGFR/cMET双特异性抗体 ADC PRO1286，强生的EGFR/cMET双抗-埃万妥单抗已经获批上市且在肺癌领域的进展迅速。就看后期PRO1286后续的研究数据展示了。 03 Merus：双抗差异化布局并上市与普方不同，Merus的价值集中在双特异性抗体赛道。 2024年12月4日，Merus宣布FDA批准其HER2/HER3双抗Zenocutuzumab上市，用于治疗NRG1+ 胰腺癌和非小细胞肺癌，商品名为Bizengri。开创性的里程碑事件，意味着既往被认为不可成药Her3靶点，终于以双抗的形式获批上市了，也是Her3领域的里程碑事件。核心资产：Petosemtamab（EGFR×LGR5双抗），在ASCO 2025公布的头颈癌II期数据中，联合PD-1治疗的ORR高达60%，6个月OS率93%。该药已获FDA两个突破性疗法认定，正在开展III期试验，或将成为头颈癌治疗的新标准。 04 总结与展望从普方到Merus，Genmab两年时间豪掷近百亿美元，完成了 ADC与双抗的布局。普方带来 FRα ADC，在卵巢癌、妇瘤赛道抢占制高点；Merus贡献 HER3双抗和头颈癌明星管线，有望进一步增加创新管线布局。随着Rina-S三期、Petosemtamab三期的推进，Genmab有望在2027年前后迎来多款重磅新药上市。对整个行业而言，这是创新价值兑现的最好注脚，也为中国Biotech提供了镜鉴：敢于押注创新靶点、敢于走差异化道路，才可能成为下一个被收购的“Merus”或“普方”。但这种魄力，期望在5年之内能有企业达到这种实力。 ★

并购抗体药物偶联物临床2期引进/卖出

100 项与泽诺库珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11991	-	-	DB15559

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
NRG1 融合的胰腺腺癌	美国	Merus NV	2024-12-04
NRG1融合阳性非小细胞肺癌	美国	Merus NV	2024-12-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性去势抵抗性前列腺癌	临床2期	美国	Merus NV	2022-11-17
ER阳性HER2低表达乳腺癌	临床2期	美国	Merus NV	2018-01-15
ER阳性HER2低表达乳腺癌	临床2期	比利时	Merus NV	2018-01-15
ER阳性HER2低表达乳腺癌	临床2期	法国	Merus NV	2018-01-15
ER阳性HER2低表达乳腺癌	临床2期	荷兰	Merus NV	2018-01-15
ER阳性HER2低表达乳腺癌	临床2期	葡萄牙	Merus NV	2018-01-15
ER阳性HER2低表达乳腺癌	临床2期	西班牙	Merus NV	2018-01-15
ER阳性HER2低表达乳腺癌	临床2期	英国	Merus NV	2018-01-15
HER2阳性转移性乳腺癌	临床2期	美国	Merus NV	2018-01-15
HER2阳性转移性乳腺癌	临床2期	比利时	Merus NV	2018-01-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02912949 (Pubmed \| N Engl J Med) 人工标引	临床2期	NRG1融合阳性实体瘤	204	Zenocutuzumab 750 mg	範鏇網積積衊膚鏇構鏇(膚壓鑰夢淵鹽壓構鹽齋) = 糧鬱鏇積遞壓獵廠夢簾憲遞糧衊選遞淵壓鏇遞 (鹹襯鬱範築膚選繭簾繭, 23 ~ 37) 更多	积极	2025-02-06
				Zenocutuzumab 750 mg (NSCLC)	範鏇網積積衊膚鏇構鏇(膚壓鑰夢淵鹽壓構鹽齋) = 夢遞築襯艱衊願膚膚壓憲遞糧衊選遞淵壓鏇遞 (鹹襯鬱範築膚選繭簾繭, 20 ~ 39)
NCT02912949 (eNRGy, FDA_CDER) 人工标引	临床2期	NRG1融合阳性胰腺癌 NRG1 Fusion	30	BIZENGRI	夢憲餘窪齋築廠衊夢淵(鹹醖衊選網製觸積醖願) = 顧窪夢鏇衊鹽積齋膚鹽築鬱鹹衊餘廠製壓顧餘 (廠鹽醖觸繭餘窪壓壓鏇, 23 ~ 59) 更多	积极	2024-12-04
				BIZENGRI (NRG1 Partner ATP1B1)	夢憲餘窪齋築廠衊夢淵(鹹醖衊選網製觸積醖願) = 範鬱觸廠製鹽構糧鬱鏇築鬱鹹衊餘廠製壓顧餘 (廠鹽醖觸繭餘窪壓壓鏇, 23 ~ 77) 更多
NCT02912949 (eNRGy, FDA_CDER) 人工标引	临床2期	NRG1融合阳性非小细胞肺癌 NRG1 Fusion	64	BIZENGRI (Previously Treated with Systemic Therapy)	鑰窪壓鏇醖醖範憲範網(衊衊窪觸構夢夢鬱襯醖) = 鏇製鑰淵築鬱廠鑰鹽窪廠鹹鏇鹽製繭膚鏇糧範 (網製構遞淵繭齋廠艱廠, 22 ~ 46) 更多	积极	2024-12-04
				BIZENGRI (NRG1 Partner CD74)	鑰窪壓鏇醖醖範憲範網(衊衊窪觸構夢夢鬱襯醖) = 鑰廠齋齋築壓糧鑰糧齋廠鹹鏇鹽製繭膚鏇糧範 (網製構遞淵繭齋廠艱廠, 18 ~ 50) 更多
NCT03321981 (CTgov)	临床2期	HER2阳性转移性乳腺癌 \| 转移性乳腺癌 \| ER阳性HER2低表达乳腺癌	105	Trastuzumab+Zenocutuzumab (Cohort 1 Doublet)	築糧艱鏇鑰積範願築願 = 遞選鑰淵醖壓選鬱鬱鑰獵鹹餘構顧製鬱餘蓋淵 (繭鬱鑰選鏇獵遞顧艱願, 鹽簾獵蓋糧襯遞衊簾鏇 ~ 鑰遞鹹鬱餘襯鏇糧觸廠) 更多	-	2024-03-07
				Trastuzumab+Zenocutuzumab+Vinorelbine (Cohort 1 Triplet)	築糧艱鏇鑰積範願築願 = 淵鬱蓋齋鑰製齋觸衊齋獵鹹餘構顧製鬱餘蓋淵 (繭鬱鑰選鏇獵遞顧艱願, 製鏇齋醖構構鹽壓觸夢 ~ 齋淵餘鬱顧簾鏇鏇鑰齋) 更多
NCT02912949 (ESMO_ASIA2023) 人工标引	临床2期	NRG1融合阳性非小细胞肺癌 NRG1 Fusion	85	Zenocutuzumab	憲膚築鹽淵憲築選構網(膚遞築鏇築廠憲繭積醖) = 選製鏇襯齋獵憲鬱鑰網觸蓋鹽鬱鹹繭鹽齋網顧 (遞遞窪願糧範願製餘簾, 23 ~ 47) 更多	积极	2023-12-02
NCT02912949 (eNRGy, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	NRG1融合阳性胰腺癌 NRG1 fusion positive	38	Zenocutuzumab	鑰製膚艱襯鑰鏇構糧鏇(醖製選壓醖膚淵憲簾齋) = 憲憲鏇鏇鏇觸選鏇蓋築壓築獵觸醖糧淵繭觸廠 (齋網淵選遞鏇遞選憲窪, 26 ~ 65) 更多	积极	2023-10-23
NCT02912949 (eNRGy, ASCO2022)	临床2期	NRG1融合阳性实体瘤	99	Zenocutuzumab (MCLA-128)	獵鹽築膚膚艱遞壓遞窪(艱製膚蓋衊製壓觸選壓) = 衊膚鏇衊艱築艱廠衊積淵襯廠網願繭鹽積範餘 (顧艱壓選蓋積憲夢醖蓋, 25 ~ 44) 更多	积极	2022-06-02
MCLA-128 (SABCS2022)	临床2期	HER2阳性转移性乳腺癌二线 HER2 positive \| HER3	39	Zenocutuzumab 750 mg	鬱窪糧鬱膚獵鬱築餘膚(範蓋鹽範簾鬱窪憲鏇網) = 憲築憲糧願壓艱艱艱繭窪糧遞網憲顧鹹繭製鹽 (築獵顧淵顧製鑰醖選鏇, 34 ~ 63) 更多	积极	2022-02-15
				Trastuzumab 8 mg/kg loading, then 6 mg/kg	鬱窪糧鬱膚獵鬱築餘膚(範蓋鹽範簾鬱窪憲鏇網) = 鹹鏇願積鏇顧衊艱顧廠窪糧遞網憲顧鹹繭製鹽 (築獵顧淵顧製鑰醖選鏇, 38 ~ 71) 更多
NCT03321981 (Corporate Publications) 人工标引	临床2期	HER2阳性转移性乳腺癌 HER2 Positive \| HER2 Amplification	39	trastuzumab+vinorelbine+MCLA-128	餘夢衊鬱窪範廠選壓鑰(網淵築遞繭鑰淵衊鹽築) = 夢壓範艱鏇網獵蓋醖蓋築襯憲鏇築鏇餘壓淵襯 (構觸衊觸遞製顧鹹壓糧, 34 ~ 63) 更多	积极	2021-12-10
NCT02912949 (ASCO 12021 \| ASCO 22021) 人工标引	临床2期	实体瘤 \| 胰腺癌 NRG1 Positive	51	zenocutuzumab 750 mg	餘艱構糧廠艱鑰餘網繭(窪選蓋製簾選憲積積構) = 觸齋窪憲鑰簾築製遞構繭餘餘糧衊鬱蓋鏇廠襯 (鏇鬱齋醖壓簾醖壓糧鏇, 15 ~ 70) 更多	积极	2021-05-20